Professor Michael J Cork
BSc MB PhD FRCP
Clinical Medicine, School of Medicine and Population Health
Professor of Dermatology
Full contact details
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
91直播
S10 2RX
- Profile
-
For enquiries please contact - ClinMed-Operational@sheffield.ac.uk
I joined the University of 91直播 in 1991 as a lecturer in dermatology whilst continuing as a practising dermatologist for the NHS in 91直播. I had previously been a Registrar in Dermatology at the Royal Hallamshire Hospital, 91直播, and before that a Registrar in Respiratory General Medicine at Leeds General Infirmary.
I have been closely involved with research in many areas of dermatology; including Atopic Eczema(dermatitis), Psoriasis, Vitiligo and the Genetics of Skin Disease. My major current research work is aimed at identifying gene–environment interactions in the development of atopic dermatitis leading to skin barrier breakdown and the understanding of how topical agents interact with the skin barrier; using this information to enhance the treatment of atopic dermatitis.
I am currently Head of 91直播 Dermatology Research in the School of Medicine & Population Health at the University of 91直播 and am Honorary Consultant Dermatologist to both 91直播 Children?s Hospital NHS Foundation Trust and to 91直播 Teaching Hospitals NHS Foundation Trust; my time is evenly split between the University and the NHS.
- Research interests
-
My research interests are inflammatory skin disorders including: atopic dermatitis (atopic eczema), psoriasis, alopecia areata and vitiligo. The group which includes both clinical and non-clinical staff has identified genetic variants associated with all of these diseases.
Internationally, 91直播 Dermatology Research is one of the leading groups translating basic dermatological science into new treatments for the clinic. Examples include `Skin Protease Inhibitors? and `Vitamin A Metabolic Pathway Inhibitors?. In 2001, with help from The Wellcome Trust, the group formed a `spin-out? company called `Molecular SkinCare?, with the aim of developing these treatments.
Another major focus of the group is the effect of topical pharmaceuticals, cosmetics and oils on the structure and function of the skin barrier. Research in this area comprises investigation of the skin barrier defect associated with skin disorders such as atopic dermatitis, how skin barrier defects develop and how to treat or repair the skin barrier defect. This includes the determination of the effect of topical agents/products on the skin of volunteers visiting our clinical diagnostic `skin laboratory?, where we can measure specific properties of the skin barrier, non-invasively, using an array of specialised equipment. These results are then correlated with variants in the genes that determine the structure and function of the skin barrier.
Research conducted by 91直播 Dermatology Research is at the interface between the clinic, academia and industry. Work has been funded by charities, including: The Wellcome Trust, British Skin Foundation and Psoriasis Association; also by the Kuwait Ministry of Health; and by pharmaceutical/cosmetics companies; including Astellas, Johnson & Johnson and Stiefel-GSK.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . The Lancet, 400(10356), 908-919.
- . The Lancet, 395(10228), 962-972.
- . New England Journal of Medicine, 375, 2335-2348.
- . British Journal of Dermatology, 175(4), 713-720.
- . Skin Pharmacology and Physiology, 29(3), 135-147.
- . Acta Dermato Venereologica, 96(3), 323-330.
- . Acta Dermato Venereologica, 95(6), 653-658.
- . Journal of Allergy and Clinical Immunology, 134(4), 818-823.
- . Br J Dermatol, 170(4), 914-921.
- . Cochrane Database Syst Rev..
- . JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing.
- . Pediatr Dermatol, 30(1), 42-50.
- . Br J Dermatol, 165(2), 329-334.
- . J Invest Dermatol, 129(8), 1892-1908.
- . British Journal of Dermatology.
Chapters
- Neonatal Skin Care and Toxicology In Eichenfield LF, Frieden IJ, Zaenglein A & Mathes E (Ed.), Neonatal and Infant Dermatology (pp. 46-56). Saunders
- The Skin Barrier in Atopic Dermatitis. In Irvine A, Hoeger P & Yan A (Ed.), Textbook of Pediatric Dermatology, UK: Blackwell Publishing Ltd..
Reports
All publications
Journal articles
- . J Dermatolog Treat, 35(1), 2296851.
- . Annales de Dermatologie et de Vénéréologie - FMC, 4(8), A205-A206.
- . Annales de Dermatologie et de Vénéréologie - FMC, 4(8), A370-A371.
- . Archives of Dermatological Research, 316(10).
- . Annals of Allergy, Asthma & Immunology, 133(6), S100-S100.
- . Annals of Allergy, Asthma & Immunology, 133(6), S96-S97.
- . Value in Health, S1098-3015(24)02861.
- . Journal of the American Academy of Dermatology, S0190-9622(24)02896.
- . British Journal of Dermatology, ljae342.
- . Journal of the American Academy of Dermatology, 91(3), AB189-AB189.
- . Journal of the American Academy of Dermatology, 91(3), AB259-AB259.
- . Journal of the American Academy of Dermatology, 91(3), AB34-AB34.
- . Journal of the American Academy of Dermatology, 91(3), AB34-AB34.
- . Journal of the American Academy of Dermatology, 91(3), AB1-AB1.
- . Skin Pharmacology and Physiology, 1-10.
- . Journal of Investigative Dermatology, 144(8), S48-S48.
- . Clinical and Translational Science, 17(8).
- . British Journal of Dermatology, ljae287.
- . British Journal of Dermatology, ljae276.
- . British Journal of Dermatology, 191(Supplement_1), i55-i56.
- . British Journal of Dermatology, 191(Supplement_1), i61-i62.
- . British Journal of Dermatology, 191(Supplement_1), i30-i30.
- . British Journal of Dermatology, 191(Supplement_1), i2-i3.
- . Revue Fran?aise d'Allergologie, 64, 104044-104044.
- . British Journal of Dermatology, 190(Supplement_2), ii47-ii48.
- . Journal of Allergy and Clinical Immunology, 153(2), AB5-AB5.
- . Air Quality, Atmosphere & Health, 17(6), 1295-1305.
- . Annales de Dermatologie et de Vénéréologie - FMC, 3(8), A363-A364.
- . Journal of Allergy and Clinical Immunology.
- . Dermatology and Therapy, 13, 2697-2719.
- . British Journal of Dermatology, ljad281.
- . Clinical and Translational Allergy, 13(9).
- . Clinical & Experimental Allergy.
- . Dermatology and Therapy, 13(9), 1987-2000.
- . British Journal of Dermatology, 189(5), 531-539.
- . Biomedical Optics Express, 14(8), 4126-4126.
- . JAMA Dermatology, 159(6), 596-596.
- . American Journal of Clinical Dermatology, 24(5), 787-798.
- . Frontiers in Virology, 3.
- . American Journal of Clinical Dermatology, 24, 609-621.
- . British Journal of Dermatology, 189(2), 238-240.
- . Journal of Dermatological Treatment, 34(1).
- . Clinical and Experimental Dermatology, 48(8), 881-888.
- . Revue Fran?aise d'Allergologie, 63(3), 103434-103434.
- . Revue Fran?aise d'Allergologie, 63(3), 103436-103436.
- . Clinical and Translational Allergy, 13(3).
- . The Journal of Allergy and Clinical Immunology: In Practice.
- Supplement Individual Article: The Importance of a Healthy Skin Barrier From the Cradle to the Grave Using Ceramide-Containing Cleansers and Moisturizers: A Review and Consensus. Journal of drugs in dermatology : JDD, 22(2), s3-SF344607s.
- . Journal of Allergy and Clinical Immunology, 151(2), AB149-AB149.
- . Pediatric Drugs, 25, 67-77.
- . Journal of Investigative Dermatology.
- . Annales de Dermatologie et de Vénéréologie - FMC, 2(8), A342-A343.
- . Annales de Dermatologie et de Vénéréologie - FMC, 2(8), A335-A336.
- . Allergy.
- . The Lancet, 400(10356), 908-919.
- . American Journal of Clinical Dermatology, 23(3), 365-383.
- . JID Innovations.
- . Revue Fran?aise d'Allergologie et d'Immunologie Clinique, 62(3), 321.
- . Annals of Allergy, Asthma & Immunology.
- . Clinical and Experimental Dermatology.
- . British Journal of Dermatology.
- . Annales de Dermatologie et de Vénéréologie - FMC, 1(8), A345-A346.
- . Annales de Dermatologie et de Vénéréologie - FMC, 1(8), A354-A355.
- . Annales de Dermatologie et de Vénéréologie - FMC, 1(8), A348-A348.
- . Allergy.
- . Journal of the European Academy of Dermatology and Venereology.
- . Annals of Allergy, Asthma & Immunology, 127(5), S16-S17.
- . Annals of Allergy, Asthma & Immunology, 127(5), S54-S55.
- . Annals of Allergy, Asthma & Immunology, 127(5), S53-S54.
- . Dermatology and Therapy, 11, 1643-1656.
- . Dermatitis, 32(1S), S81-S91.
- . Allergy and Asthma Proceedings, 42(5), 425-431.
- . Pediatric Drugs, 23(5), 515-527.
- . Biomedical Optics Express, 12(6), 3296-3311.
- . Journal of Investigative Dermatology, 141(5), s84.
- Treatment outcomes of patients with atopic dermatitis (AD) treated with dupilumab through the early access to medicines scheme (EAMS) in the UK. Ulster Medical Journal, 90(2), 70-76.
- . Journal of the European Academy of Dermatology and Venereology.
- . Journal of Investigative Dermatology.
- . Journal of the European Academy of Dermatology and Venereology.
- . Journal of the European Academy of Dermatology and Venereology, 35(2), 464-475.
- . Journal of Allergy and Clinical Immunology, 147(2), AB28-AB28.
- . Journal of Allergy and Clinical Immunology, 147(2), ab156.
- . British Journal of Dermatology.
- . Annales de Dermatologie et de Vénéréologie, 147(12), A362-A362.
- . Journal of the American Academy of Dermatology, 83(6), AB71-AB71.
- . Journal of the American Academy of Dermatology, 83(6), AB39-AB39.
- . Journal of the European Academy of Dermatology and Venereology.
- . Annals of Allergy, Asthma & Immunology, 125(5), S40-S41.
- . Annals of Allergy, Asthma & Immunology, 125(5), S46-S46.
- . British Journal of Dermatology.
- . British Journal of Dermatology.
- . The Lancet, 396(10246), 255-266.
- . Journal of Dermatological Treatment.
- . Dermatology and Therapy.
- . Journal of the American Academy of Dermatology.
- . Journal of the American Academy of Dermatology.
- . Journal of the European Academy of Dermatology and Venereology.
- . The Lancet, 395(10228), 962-972.
- . Pediatric Dermatology, 37(1), 130-136.
- . British Journal of Dermatology, 182(1), e47-e47.
- . British Journal of Dermatology, 182(1), e30-e30.
- . British Journal of Dermatology, 182(3), 729-737.
- . BMJ Open, 9(8).
- . Journal of the European Academy of Dermatology and Venereology, 33(9), 1644-1659.
- . Journal of Dermatological Treatment.
- . British Journal of Dermatology, 180(6), 1312-1338.
- . Journal of the European Academy of Dermatology and Venereology.
- . Journal of the European Academy of Dermatology and Venereology, 33(5), 807-815.
- . British Journal of Dermatology.
- . British Journal of Dermatology, 181(1), 37-54.
- . Journal of the American Academy of Dermatology, 79(2), e25-e26.
- . BioMed Research International, 2018.
- . British Journal of Dermatology, 178(5), e366-e366.
- . British Journal of Dermatology, 178(5), e385-e385.
- . British Journal of Dermatology, 178(5), 1083-1101.
- . British Journal of Dermatology, 178(4), 839-853.
- . Biomedical Optics Express, 9(4), 2001-2001.
- . British Journal of Dermatology, 179(6), 1297-1306.
- . Journal of Investigative Dermatology, 138(1), 68-77.
- . Annales de Dermatologie et de Vénéréologie, 144(12), S266-S267.
- . Annals of Allergy, Asthma & Immunology, 119(5), S94-S95.
- . British Journal of Dermatology, 177(5), 1170-1201.
- . Journal of the American Academy of Dermatology, 77(4), 623-633.
- . British Journal of Dermatology, 177(3), 608-609.
- . Trials, 18(1), 343-343.
- . Dermatol Ther (Heidelb).
- . Royal Society of London. Philosophical Transactions A. Mathematical, Physical and Engineering Sciences, 375(2096).
- . Dermatology and Therapy.
- . British Journal of Dermatology, 177(3), 628-636.
- Biologic Treatments for Atopic Eczema: Anti IL-4 and IL-13 biologics. Exchange: National Eczema Society Members' Magazine(163), 11-18.
- . British Journal of Dermatology, 176(2), 317-329.
- . British Journal of Dermatology, 176(1), 20-43.
- . British Journal of Dermatology, 176(1), 44-51.
- . New England Journal of Medicine, 375, 2335-2348.
- . Journal of Allergy and Clinical Immunology, 138(5), 1715-1719.e4.
- . British Journal of Dermatology, 175(5), 1011-1019.
- . British Journal of Dermatology, 175(4), 713-720.
- . British Journal of Dermatology, 175(1), 23-44.
- . Skin Pharmacology and Physiology, 29(3), 135-147.
- . Pediatric Dermatology, 33(3), 311-321.
- . Acta Dermato Venereologica, 96(3), 323-330.
- . Pediatric Allergy and Immunology, 26(4), 306-315.
- . Acta Dermato Venereologica, 95(6), 653-658.
- . Cochrane Database of Systematic Reviews, 2014(12), 1-16.
- . Alergologia Polska - Polish Journal of Allergology, 1(4), T33-T41.
- . Journal of Allergy and Clinical Immunology, 134(4), 818-823.
- . Br J Dermatol, 170(4), 914-921.
- Topical Treatments for Chronic Plaque Psoriasis. Journal of the American Academy of Dermatology(In Press).
- . JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 69(5), 799-807.
- . BRITISH JOURNAL OF DERMATOLOGY, 169(3), 519-527.
- . Clinical and Experimental Dermatology, 38(3), 231-238.
- . Cochrane Database Syst Rev..
- . Br J Dermatol, 168(2), 235-236.
- . Progress in Biomedical Optics and Imaging - Proceedings of SPIE, 8565.
- . BMC Dermatol, 13, 7.
- . JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing.
- . Pediatr Dermatol, 30(1), 42-50.
- . BMC Pediatrics, 12.
- . Nature Genetics.
- . JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 41(6).
- . Human Molecular Genetics, 21(23), 5185-5192.
- Atopic dermatitis: A candidate for disease-modifying strategy. Allergy: European Journal of Allergy and Clinical Immunology.
- . BRITISH JOURNAL OF DERMATOLOGY, 165(6), 1159-1160.
- . CONTACT DERMATITIS, 65(4), 208-212.
- . Archives of Disease in Childhood - Fetal and Neonatal Edition, 96(Supplement 1), Fa43-Fa43.
- . Br J Dermatol, 164(6), 1179-1180.
- . BMC PEDIATR, 11.
- . Br J Dermatol, 165(2), 329-334.
- . Contact Dermatitis, 65(4), 208-212.
- . J Hum Genet, 56(6), 423-427.
- . DERMATOLOGY, 222(1), 36-48.
- . British Journal of Midwifery, 19(6), 354-362.
- . J Dermatol Sci, 61(2), 131-133.
- . Nat Genet, 42(11), 985-990.
- . J Invest Dermatol, 129(8), 1892-1908.
- . Br J Nurs, 18(14), 872-877.
- . J EUR ACAD DERMATOL, 23(7), 751-759.
- A qualitative study exploring women's and health professionals' views of newborn bathing practices. Evidence Based Midwifery, 7(4), 112-121.
- . COCHRANE DB SYST REV(2).
- . Br J Dermatol, 159(3), 591-596.
- . Eur J Hum Genet, 16(8), 1002-1009.
- . Dermatitis, 19(4), 218-238.
- . Br J Dermatol, 159(1), 77-85.
- . Tissue Antigens, 71(3), 206-212.
- . Drug Discovery Today: Disease Mechanisms, 5(1).
- . Allergy, 62(5), 514-519.
- . DERMATOLOGY, 215, 27-44.
- . Hum Immunol, 67(7), 535-539.
- . J Allergy Clin Immunol, 118(1), 3-21.
- . J Med Ethics, 32(3), 133-137.
- . HUM MOL GENET, 15(4), 519-529.
- . Cytokine, 33(2), 72-78.
- . PEDIATRICS, 117(1), E118-E128.
- . J AM ACAD DERMATOL, 54(1), 1-15.
- Predisposition to sensitive skin and atopic eczema.. Community Pract, 78(12), 440-442.
- . Br J Dermatol, 153(2), 372-377.
- . Pediatric Dermatology, 22(4), 373-374.
- . J Invest Dermatol, 124(3), 545-552.
- . DERMATOLOGY, 211(2), 77-78.
- . J Dermatol Sci, 35(3), 171-179.
- . J Invest Dermatol, 123(1), 62-66.
- . Journal of Dermatological Treatment, 14(3), 190-191.
- . Br J Dermatol, 149(3), 582-589.
- . Hum Genet, 112(4), 400-403.
- Eumovate (clobetasone butyrate 0.05%) cream: a review of clinical efficacy and safety.. The Journal of dermatological treatment, 14(2), 71-85.
- An audit of adverse drug reactions to aqueous cream in children with atopic eczema. Pharmaceutical Journal, 271(7277), 747-748.
- . Tissue Antigens, 60(6), 489-495.
- Role of the autoimmune regulator (AIRE) gene in alopecia areata: Strong association of a potentially functional AIRE polymorphism with alopecia universalis. J INVEST DERMATOL, 119(3), 719-719.
- Tumour necrosis factor-alpha induced up-regulation of elafin and antileukoprotease enhances the skin barrier. J INVEST DERMATOL, 119(3), 729-729.
- . Mechanisms of Development, 114(1-2), 205-212.
- Topical preparations for the treatment of psoriasis: a systematic review. BRIT J DERMATOL, 146(3), 351-364.
- . Eur J Immunogenet, 29(1), 25-30.
- Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL1-L1 in alopecia areata: Strong disease associations and possible gene interaction. J INVEST DERMATOL, 117(2), 431-431.
- . Heredity (Edinb), 87(Pt 2), 215-219.
- . Human Genetics, 106(6), 639-645.
- . Hum Genet, 106(6), 639-645.
- . British Journal of Dermatology, 142(3), 351-364.
- Corrigendum: Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis (Human Molecular Genetics (2000) 8 (1135-1140)). Human Molecular Genetics, 9(4), 659.
- Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. BRIT J DERMATOL, 142(1), 52-58.
- . Lancet, 354(9178), 597.
- . Hum Mol Genet, 8(6), 1135-1140.
- Genetic association between MHC S gene and susceptibility to psoriasis. J INVEST DERMATOL, 112(4), 591-591.
- Genetic susceptibility and disease behaviour in Crohns disease: The role of tumour necrosis factor alpha gene promoter polymorphisms. GUT, 44, A29-A29.
- The tumor necrosis factor alpha gene promoter polymorphisms and Crohns disease: Study of genetic suscepibility and disease behavior. GASTROENTEROLOGY, 116(4), A678-A678.
- Treatment of psoriasis: day care vs. inpatient therapy. BRIT J DERMATOL, 140(2), 375-376.
- Taking the itch out of eczema: How the careful use of emollients can break the itch-scratch cycle of atopic eczema. Asthma Journal, 4(3), 116-120.
- . Br J Dermatol, 140(1), 73-78.
- A retrospective cost-effectiveness analysis of the treatment of onychomycosis in general practice. BRIT J DERMATOL, 139(4), 660-664.
- Vitamin D receptor polymorphism and calcipotriol response in patients with psoriasis. J INVEST DERMATOL, 110(3), 301-302.
- The importance of skin barrier function. J DERMATOL TREAT, 8, S7-S13.
- Cytokine dermatosis: Reactivation of eczema during interleukin-2 infusion. BRIT J DERMATOL, 136(4), 644-645.
- Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis. BRIT J DERMATOL, 136(1), 147-148.
- . Dermatol Clin, 14(4), 671-678.
- . Exp Dermatol, 5(4), 227-229.
- . Journal of the European Academy of Dermatology and Venereology, 7(S1).
- Cyclosporine in severe childhood atopic dermatitis: A multicenter study. J AM ACAD DERMATOL, 34(6), 1016-1021.
- . Hum Genet, 97(6), 723-726.
- . Human Genetics, 97(6), 723-726.
- NOVEL GENETIC ASSOCIATION OF AN IL-1-BETA GENE VARIATION AT-+3953, SUSCEPTIBILITY TO PSORIASIS AND IL-1-BETA PROTEIN-PRODUCTION. J INVEST DERMATOL, 105(3), 453-453.
- TREATMENT OF GROVERS-DISEASE WITH CALCIPOTRIOL (DOVONEX(R)). BRIT J DERMATOL, 132(5), 832-833.
- . J Invest Dermatol, 104(5), 856-858.
- . J Invest Dermatol, 104(5 Suppl), 15S-16S.
- . Hum Genet, 94(4), 407-410.
- ASSOCIATION OF THE INTERLEUKIN ONE RECEPTOR ANTAGONIST GENE POLYMORPHISM WITH LICHEN-SCLEROSUS. J INVEST DERMATOL, 103(3), 408-408.
- . Arthritis Rheum, 37(9), 1380-1385.
- . J Invest Dermatol, 103(3), 387-390.
- . Contact Dermatitis, 30(4), 214-216.
- Psoriasis and interleukin-1. A translation.. J R Coll Physicians Lond, 27(4), 366.
- . Journal of Dermatological Science, 6(1), 18-18.
- . Journal of Dermatological Science, 6(1), 2-2.
- INTERLEUKIN ONE RECEPTOR ANTAGONIST POLYMORPHISM - ALLELIC ASSOCIATION WITH INFLAMMATORY DERMATOSES. J INVEST DERMATOL, 100(4), 448-448.
- GENETICS OF INTERLEUKIN ONE RECEPTOR ANTAGONIST IN INFLAMMATORY SKIN DISEASES. J INVEST DERMATOL, 100(4), 522-522.
- GENETICS OF INTERLEUKIN ONE RECEPTOR ANTAGONIST IN INFLAMMATORY SKIN DISEASES. CLIN RES, 41(2), A179-A179.
- . Journal of Dermatological Treatment, 4(3), 119-122.
- . Contact Dermatitis, 28(1), 40-41.
- . Eur J Pediatr, 152(4), 291-292.
- . Br J Dermatol, 126(1), 16-18.
- PYODERMA-GANGRENOSUM. BRIT MED J, 303(6807), 925-925.
- . Contact Dermatitis, 25(3), 200-201.
- . BMJ, 301(6765), 1398-1398.
- . British Journal of Haematology, 63(4), 775-783.
- . Leukemia Research, 6(4), 553-565.
- The regulation of the haematopoietic stem cell compartment in foetal liver.. Progress in clinical and biological research, 59 B, 277-285.
- . Leukemia Research, 5(1), 101-105.
- The control of haematopoietic stem cell proliferation by humoral factors.. Progress in clinical and biological research, 59 B, 269-276.
- Changes in the growth fraction of haempoietic stem cells following treatment with normal rat bone marrow extract. Cell and Tissue Kinetics, 13(2), 211-212.
- . Applied Spectroscopy.
- . Pediatric Dermatology.
- . JEADV Clinical Practice.
- . JEADV Clinical Practice.
- . Dermatology and Therapy.
- . Health Technology Assessment, 1-116.
- . American Journal of Clinical Dermatology.
- . SKIN The Journal of Cutaneous Medicine, 8(2), s379-s379.
- . SKIN The Journal of Cutaneous Medicine, 8(2), s377-s377.
- . Acta Dermato-Venereologica, 104, adv13467-adv13467.
- . Drug Design, Development and Therapy, Volume 18, 277-289.
- . Pediatric Drugs.
- . SKIN The Journal of Cutaneous Medicine, 8(1), s329-s329.
- . SKIN The Journal of Cutaneous Medicine, 8(1), s323-s323.
- . Dermatology and Therapy.
- . Clinical and Experimental Dermatology.
- . American Journal of Clinical Dermatology.
- . SKIN The Journal of Cutaneous Medicine, 7(2), s140-s140.
- . SKIN The Journal of Cutaneous Medicine, 7(2), s139-s139.
- . JAMA Dermatology.
- . SKIN The Journal of Cutaneous Medicine, 6(6), s77-s77.
- . Cochrane Database of Systematic Reviews, 2022(11).
- . Pediatric Dermatology.
- . Pediatric Dermatology.
- . Clinical & Experimental Allergy.
- . Cochrane Database of Systematic Reviews.
- . SKIN The Journal of Cutaneous Medicine, 5(1), s12-s12.
- . SKIN The Journal of Cutaneous Medicine, 5(1), s9-s9.
- . SKIN The Journal of Cutaneous Medicine, 5(1), s13-s13.
- . Clinical & Experimental Allergy.
- . SKIN The Journal of Cutaneous Medicine, 4(6), s98-s98.
- . SKIN The Journal of Cutaneous Medicine, 4(6), s104-s104.
- . Journal of the European Academy of Dermatology and Venereology.
- . Cochrane Database of Systematic Reviews.
- . Cochrane Database of Systematic Reviews.
- . Cochrane Database of Systematic Reviews.
- . Journal of Dermatological Treatment.
- . British Journal of Dermatology.
- . Dermatology and Therapy.
- . Clinical & Experimental Allergy.
Chapters
- , pH of the Skin: Issues and Challenges (pp. 95-107). S. Karger AG
- Neonatal Skin Care and Toxicology In Eichenfield LF, Frieden IJ, Zaenglein A & Mathes E (Ed.), Neonatal and Infant Dermatology (pp. 46-56). Saunders
- Current and Future Trends: Skin Diseases and Treatment In Benson HAE & Watkinson AC (Ed.), Topical and Transdermal Drug Delivery Wiley
- The Skin Barrier in Atopic Dermatitis. In Irvine A, Hoeger P & Yan A (Ed.), Textbook of Pediatric Dermatology, UK: Blackwell Publishing Ltd..
- , Basic and Clinical Dermatology (pp. 211-240). Informa Healthcare
- Epidermal Barrier Dysfunction in Atopic Dermatitis In Rawlings L (Ed.), Skin Moisturization USA: Informa Healthcare USA Inc..
Conference proceedings papers
- Progressive and sustained Disease Control in Patients with atopic Dermatitis (AD) aged 12 to 17 Years treated with Tralokinumab for 52 Weeks. ALLERGOLOGIE, Vol. 47(9)
- Langzeitwirksamkeit von Tralokinumab bei Jugendlichen mit mittelschwerer bis schwerer Atopischer Dermatitis. ALLERGOLOGIE, Vol. 47(9)
- Children with atopic dermatitis respond more rapidly to dupilumab treatment in comparison to adolescents and adults. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 144(8) (pp S48-S48)
- . Journal of Investigative Dermatology, Vol. 143(11) (pp S342-S342)
- . British Journal of Dermatology, Vol. 188(Supplement_3)
- . British Journal of Dermatology, Vol. 188(Supplement_3)
- . British Journal of Dermatology, Vol. 188(Supplement_3)
- . British Journal of Dermatology, Vol. 188(Supplement_3)
- . British Journal of Dermatology, Vol. 188(Supplement_2)
- Dupilumab Treatment is Not AssociatedWith an Increased Overall Risk of Infections in Patients Aged 6 Months to 5 yearsWithModerate-to-Severe Atopic Dermatitis. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 21 (pp 100-101)
- Treatment-Emergent Adverse Events in Patients Aged 6 Months to 5 Years With Moderate-to- Severe Atopic Dermatitis Treated With Dupilumab in an Open-Label Extension Clinical Trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB100-AB100)
- SAFETY OF TRALOKINUMAB IN PAEDIATRIC PATIENTS AGED 12-17 WITH MODERATE-TO-SEVERE AROPIC DERMATITIS: RESULTS FROM THE PHASE 3 ECZTRA 6 TRIAL. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 21 (pp 58-58)
- Safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB221-AB221)
- PROGRESSIVE AND SUSTAINED DISEASE CONTROL IN PATIENTS WITH ATOPIC DERMATITIS (AD) AGED 12-17 YEARS TREATED WITH TRALOKINUMAB FOR 52 WEEKS. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 30-30)
- Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB190-AB190)
- LONG-TERM EFFICACY OF TRALOKINUMAB IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 54-54)
- LONG-TERM DUPILUMAB TREATMENT IS NOT ASSOCIATED WITH AN INCREASED OVERALL RISK OF INFECTIONS IN PATIENTS AGED 6 MONTHS TO 5 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS IN AN OPENLABEL EXTENSION STUDY. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 54-54)
- Long Term Hematologic Laboratory Safety of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB62-AB62)
- Integrated Analysis of Abrocitinib for the Treatment of Adolescents with Moderate-to-Severe Atopic Dermatitis From the Phase 3 Clinical Trial Program. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 21 (pp 77-77)
- EFFICACY AND SAFETY OF DUPILUMAB TREATMENT UP TO 1 YEAR IN INFANTS AND PRESCHOOL CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 53-53)
- Dupilumab treatment normalizes skin barrier function and improves patient-reported outcomes in patients aged 6 to 11 years with moderate-to-severe atopic dermatitis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 143(11) (pp S342-S342)
- Dupilumab Treatment Improves Sleep Quality in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis and Their Caregivers. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB40-AB40)
- Sequence of improvement in atopic dermatitis signs and symptoms in patients aged 6 months to 17 years treated with dupilumab. ALLERGY, Vol. 78 (pp 196-196)
- Dupilumab treatment normalizes skin barrier function and symptoms in children aged 6-11 years with moderate-to-severe atopic dermatitis. ALLERGY, Vol. 78 (pp 194-194)
- Allergy profile for patients receiving dupilumab for severe atopic dermatitis. ALLERGY, Vol. 78
- Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: Results from an open-label extension trial. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 52(8) (pp 1014-1014)
- Dupilumab treatment is associated with reductions in serum immunoglobulin E and thymus and activation-regulated chemokine levels in children aged 6 to 11 years with severe atopic dermatitis. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 52(8) (pp 1059-1059)
- Long-term efficacy of abrocitinib after initial successful treatment in patients with atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 72-72)
- A randomized controlled trial assessing the effectiveness and safety of ciclosporin vs. methotrexate in the treatment of severe atopic eczema in children and young people: the TREatment of severe Atopic eczema Trial (TREAT). BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 13-14)
- Efficacy and safety of dupilumab in children aged >= 6 months to < 6 years with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 186(4) (pp E173-E173)
- Efficacy and safety of dupilumab in children aged 6-11 years with inadequately controlled severe atopic dermatitis: results from an open-label extension trial up to 1 year. BRITISH JOURNAL OF DERMATOLOGY, Vol. 186(4) (pp E159-E160)
- Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase III ECZTRA 6 trial. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E90-E91)
- Clinically meaningful responses achieved with tralokinumab in adults with moderate-to-severe atopic dermatitis who did not meet IGA 0/1 at initial 16-week treatment. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 142(8) (pp B17-B17)
- Dupilumab treatment improved sleep quality in moderate-to-severe atopic dermatitis in children aged 6 months-5 years and their caregivers. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E112-E113)
- A phase IIa study of amlitelimab, a novel nondepleting anti-OX40Ligand mAb in patients with moderate to severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E96-E96)
- Dupilumab treatment improves health-related quality of life in children aged 6 months-5 years with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E104-E105)
- Efficacy and safety of dupilumab in children aged >= 6 months to < 6 years with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 12-12)
- Dupilumab provides long-term efficacy over 2.5 years in adults with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 69-69)
- Dupilumab provides long-term improvement in pruritus in children with severe atopic dermatitis and adolescents and adults with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 79-79)
- Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase III ECZTRA 6 trial. BRITISH JOURNAL OF DERMATOLOGY, Vol. 186(4) (pp E145-E146)
- EFFECTS OF EMOLLIENT CREAMS ON THE SKIN BARRIER OF PATIENTS WITH ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 102 (pp 35-36)
- (pp a68.2-a6a69)
- Dupilumab is effective in children aged 6-11 years with severe atopic Dermatitis (AD) regardless of baseline serum total immunoglobulin E levels. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 51(12) (pp 1659-1659)
- Dupilumab treatment leads to mild transient increases in eosinophil levels without clinical relevance in children aged 6-11 years with severe atopic dermatitis. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 51(12) (pp 1687-1688)
- Fifty-two-week laboratory safety findings from an open-label extension study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE). BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E121-E121)
- Long-term efficacy and safety data for dupilumab in a phase III open-label extension trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with uncontrolled moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E115-E116)
- 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB120-AB120)
- Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB120-AB120)
- Dupilumab improves Eczema Area and Severity Index regional scores across all anatomical regions in children aged 6-11 years with severe atopic dermatitis (AD). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB136-AB136)
- Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs and symptoms and quality of life (QoL) in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 141(5) (pp S84-S84)
- LABORATORY SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS AGED >= 6-< 12 YEARS WITH SEVERE ATOPIC DERMATITIS: RESULTS FROM A PHASE 3 TRIAL (LIBERTY AD PEDS). ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 59-59)
- LONG-TERM EFFICACY AND SAFETY OF DUPILUMAB IN A PHASE 3 OPEN-LABEL EXTENSION TRIAL (LIBERTY AD PED-OLE) IN PATIENTS AGED >= 6 TO < 12 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 60-60)
- Long-term efficacy and safety data for dupilumab in a phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with moderate-to-severe atopic dermatitis (AD). JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 19 (pp 14-14)
- Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma. BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E110-E110)
- Impact of abrocitinib on itch, sleep, skin pain and psychological stress in patients with moderate-to-severe atopic dermatitis: pooled analysis from JADE monotherapy trials. BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E72-E73)
- Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB141-AB141)
- Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB97-AB97)
- The targeted Action on Interleukin-13 with Tralokinumab improved the Sleep in two randomized, double-blind, placebo-controlled Phase III Studies in Patients with atopic Dermatitis. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 19 (pp 56-56)
- Specifically targeting interleukin-13 with tralokinumab improved sleep in two phase III, randomized, double-blind, placebo-controlled trials in patients with atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 184(3) (pp E64-E65)
- Early changes in patient-relevant endpoints in three tralokinumab pivotal phase III trials (ECZTRA 1-3) in adult patients with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 184(3) (pp E64-E64)
- LOWERING SKIN SURFACE PH WITH A TOPICAL ZINC LACTOBIONATE PREPARATION CONTAINING PHYSIOLOGIC LIPIDS IMPROVES SKIN BARRIER STRUCTURE AND FUNCTION IN ADULTS WITH ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 51-51)
- Laboratory safety of dupilumab in paediatric patients aged >= 6 to < 12 years with severe atopic dermatitis: results from a phase III trial (LIBERTY AD PEDS). BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E122-E123)
- A RANDOMISED CONTROLLED TRIAL OF DAILY EMOLLIENT DURING INFANCY FOR PREVENTING ECZEMA - RESULTS OF THE BEEP TRIAL. ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 7-8)
- An investigation of the skin barrier restoring effects of a cream containing ceramides in a multivesicular emulsion in people with dry, eczema-prone, skin: The RESTORE study phase 2. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 83(6) (pp AB71-AB71)
- Dupilumab improves signs and symptoms in adult and adolescent patients with erythrodermic atopic dermatitis: A pooled subgroup analysis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 83(6) (pp AB39-AB39)
- The use of systemic immunomodulatory agents in the treatment of children and adolescents with atopic eczema: lessons from the UK-Irish Atopic Eczema Systemic Therapy (A-STAR) Register. BRITISH JOURNAL OF DERMATOLOGY, Vol. 183 (pp 147-148)
- Dupilumab monotherapy improves signs, symptoms and quality of life in adult and adolescent patients with erythrodermic atopic dermatitis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 140(7) (pp S60-S60)
- Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase III, JADE MONO-1 study. BRITISH JOURNAL OF DERMATOLOGY, Vol. 183(4) (pp E105-E106)
- A real-world observational study to describe National Health Service resource use for the management of moderate-to-severe atopic dermatitis in secondary care for children and adolescents aged 6-17 years. BRITISH JOURNAL OF DERMATOLOGY, Vol. 183 (pp 147-147)
- . Journal of Investigative Dermatology, Vol. 139(5) (pp s104-s104), 8 May 2019 - 11 May 2019.
- Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 139(5) (pp S104-S104)
- Clinically meaningful responses in moderate-to-severe atopic dermatitis patients treated with Dupilumab. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 17 (pp 116-116)
- Quantification of natural moisturizing factors at the skin surface using a portable infrared spectrometer device: a pilot, calibration model. BRITISH JOURNAL OF DERMATOLOGY, Vol. 179(1) (pp E35-E36)
- An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 177 (pp 155-155)
- An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 177 (pp 67-68)
- Dupilumab in moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials (SOLO 1 & 2). JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 15 (pp 79-79)
- . Proceedings of SPIE, Vol. 10037
- DUPILUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN ATOPIC DERMATITIS PATIENTS INADEQUATELY CONTROLLED, INTOLERANT, OR INADVISABLE FOR CYCLOSPORINE-A. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, Vol. 119(5) (pp S94-S95)
- Characterisation of the skin barrier defect in atopic dermatitis using in vivo ATR-FTIR spectroscopy. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 136(9) (pp S182-S182)
- A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. BRITISH JOURNAL OF DERMATOLOGY, Vol. 173 (pp 153-153)
- The effect of a complex emollient cream containing 5% urea, ceramide 3 and lactic acid, compared with a simple emollient, on the skin barrier in older people with dry skin. BRITISH JOURNAL OF DERMATOLOGY, Vol. 171 (pp 57-58)
- Feasibility study of Barrier Enhancement For Eczema Prevention (BEEP). BRITISH JOURNAL OF DERMATOLOGY, Vol. 170(6) (pp E8-E9)
- Noninvasive assessment of the lipid structure and water holding properties of the stratum corneum in vivo by ATR-FTIR using a fibre optic probe in patients with atopic dermatitis and healthy controls. BRITISH JOURNAL OF DERMATOLOGY, Vol. 170(6) (pp E29-E29)
- A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial). BRITISH JOURNAL OF DERMATOLOGY, Vol. 170(6) (pp E32-E32)
- A difficult case of atopic eczema: useful learning points. BRITISH JOURNAL OF DERMATOLOGY, Vol. 169 (pp 120-120)
- Chymotrypsin-like protease activity in the stratum corneum is increased in atopic dermatitis and upon washing with soap. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 68(4) (pp AB172-AB172)
- Skin barrier breakdown in atopic dermatitis: the effect of topical products. INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, Vol. 34(4) (pp 363-364)
- Vitamin D supplementation improves atopic dermatitis and atopic dermatitis complicated by eczema herpeticum. BRITISH JOURNAL OF DERMATOLOGY, Vol. 167 (pp 127-127)
- A randomized comparison of aqueous cream and Oilatum (R) Junior bath additive on skin barrier function in atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 165 (pp 115-115)
- A randomized comparison of aqueous cream and Oilatum (R) Junior bath additive on skin barrier function in atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 165 (pp 44-45)
- Patch testing is a useful investigation in children with eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 161 (pp 125-125)
- . BRITISH JOURNAL OF DERMATOLOGY, Vol. 161 (pp 115-116)
- Skin protease inhibitors: a new treatment for atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 161 (pp 30-31)
- Skin protease inhibitors: A new treatment for atopic dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 60(3) (pp AB67-AB67)
- Contamination of emollient creams and ointments with Staphylococcus aureus in children with atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 159 (pp 114-114)
- Vitamin A metabolic pathway inhibition: a new therapeutic approach to treating psoriasis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 159 (pp 118-118)
- Differences in the effect of topical corticosteroids and calcineurin inhibitors on the skin barrier - Implications for therapy. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 127 (pp S45-S45)
- Severe alopecia areata is associated with a functional polymorphism in the PTPN22 gene. IMMUNOLOGY, Vol. 120 (pp 70-70)
- The effects of topical corticosteroids and pimecrolimus skin barrier function, gene expression, and topical drug penetration in atopic eczema and unaffected controls. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 56(2) (pp AB69-AB69)
- Reduced and abnormal proteolysis of corneodesmosomal proteins in psoriatic skin. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 126 (pp 116-116)
- A study on the effect of genetic variants of the autoimmune regulator (AIRE) promoter, on AIRE activity and downstream Aire-regulated genes. BRITISH JOURNAL OF DERMATOLOGY, Vol. 155(1) (pp 250-250)
- A synonymous single nucleotide polymorphism in human cystatin A, a candidate gene in the PSORS5 locus, confers susceptibility to psoriasis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 155(1) (pp 235-235)
- Interaction of topical corticosteroids and pimecrolimus with the skin barrier: Implications for efficacy and safety of treatment for atopic dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 54(3) (pp AB3-AB3)
- Skin barrier damage: Cause or consequence of atopic dermatitis?. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 125(3) (pp 605-605)
- Treatment of atopic dermatitis from a skin barrier perspective. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 125(3) (pp 611-611)
- Skin barrier damage: Cause or consequence of atopic dermatitis?. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 52(3) (pp P9-P9)
- An audit of adverse drug reactions to aqueous cream in children with atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 151 (pp 57-58)
- Abnormal proteolysis of corneodesmosin in psoriatic skin. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 121(6) (pp 1568-1568)
- Role of variants within genes regulating the skin barrier in the pathogenesis of atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 149 (pp 4-4)
- Genetic analysis of the autoimmune regulator (aire) gene: potential role of aire in susceptibility to alopecia universalis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 148(4) (pp 849-850)
- Alopecia areata: age at onset, atopy & disease associations. BRITISH JOURNAL OF DERMATOLOGY, Vol. 148(4) (pp 866-867)
- . Journal of Investigative Dermatology Symposium Proceedings, Vol. 4(3) (pp 199-199)
- . Journal of the European Academy of Dermatology and Venereology, Vol. 7 (pp S31-S37)
- . SKIN The Journal of Cutaneous Medicine, Vol. 6(2) (pp s29-s29)
Reports
Posters
- 41343 Safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis.
- 41817 Dupilumab Treatment Improves Sleep Quality in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis and Their Caregivers.
- 43997 Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND.
- 42924 Treatment-Emergent Adverse Events in Patients Aged 6 Months to 5 Years With Moderate-to- Severe Atopic Dermatitis Treated With Dupilumab in an Open-Label Extension Clinical Trial.
- 42008 Long Term Hematologic Laboratory Safety of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis.
- P24 Emollient use and effects on cutaneous allergen reactions: a preliminary study.
- P40 Dupilumab treatment restores skin barrier function in lesional and nonlesional skin of patients with atopic dermatitis and improves patient-reported outcomes.
- P73 Laboratory safety from a 16-week phase III study of dupilumab in patients aged 6?months–5?years with moderate-to-severe atopic dermatitis.
- P81 Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND.
- 392 Safety of amlitelimab in a Phase 2a clinical trial of patients with moderate-to-severe atopic dermatitis.
- 353 Amlitelimab reduces serum IL-13 in a phase 2a clinical trial in atopic dermatitis without impacting T-cell expansion in a T-cell recall assay.
- 345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis.
- 34326 Real-world analysis of skin infections and antimicrobial use among patients with atopic dermatitis before and after initiation of dupilumab treatment.
- 34312 Treatment with amlitelimab (KY1005, SAR445229): A novel nondepleting anti-OX40Ligand (OX40L) mAb reduces IL-13 serum levels in a phase 2a randomized placebo-controlled trial in patients with moderate to severe atopic dermatitis.
- 33569 Optimization of common hand cleansers for protection from viral spread and occupational hand dermatoses.
- 34655 Integrated analysis of abrocitinib for the treatment of adolescents with moderate-to-severe atopic dermatitis from the phase 3 clinical trial program.
- 33781 Sustained and durable response up to 24 weeks after last dose observed in a phase 2a study (NCT03754309) of amlitelimab (KY1005, SAR445229) a novel nondepleting anti-OX40Ligand (OX40L) mAb in patients with moderate to severe atopic dermatitis (AD).
- LB946 Clinically meaningful responses achieved with tralokinumab in adults with moderate-to-severe atopic dermatitis who did not meet IGA 0/1 at initial 16-week treatment.
- 27394 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial.
- 27350 Dupilumab improves Eczema Area and Severity Index regional scores across all anatomical regions in children aged 6–11 years with severe atopic dermatitis (AD).
- 26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD).
- 26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE).
- Teaching interests
-
My teaching interests within The University include medical undergraduate lecturing and in-clinic training plus postgraduate researcher training and mentoring. I also lecture to related courses at other universities, such as the MSc in Dermatology at Cardiff and at major international and national conferences in the field of dermatology. In addition I undertake a large number of atopic eczema related educational presentations at local, national and international level to a wide range of audiences including; pharmacists, general practitioners, hospital nurses, community nurses, midwives, paediatricians, practice nurses and patient support charities (e.g. National Eczema Society, Skin Care Campaign and Psoriasis Association).
Education of Children with Skin Diseases:
I have developed a special interest in `translating? the complex pathophysiology of skin disease into cartoons and language that can be understood by a child of six. I presented these to the National Eczema Society and the Skin Care Campaign. I have written papers for these charities describing the content of the lectures, for example Cork et al 2000; 2002 "Skin Wars". I use the cartoons in my clinics to teach children and their parent about skin diseases. The medical students that sit-in during my clinics, suggested I incorporated the "Skin Wars" cartoons into their lectures because they made dermatology exciting. The "Skin Wars" cartoons have been disseminated to many other dermatology departments. I have assigned all commercial profits from use of the "Skin Wars" cartoons to the National Eczema Society. The "Skin Wars" teaching approach was cited as being an innovative approach to education by the judges in the Hospital Doctor Dermatology Team of the Year Awards, which our paediatric dermatology team won in 2001. This teaching method was also highlighted in the National Eczema Society Health Care Professionals Award 2004.
- Professional activities and memberships
-
- Member of the National Institute of Clinical Excellence (NICE) clinical guideline development group for the treatment of Atopic Eczema in children.
- Advisor, Lecturer and developer of educational materials for the National Eczema Society, Skin Care Campaign, Psoriasis Association and Allergy UK.
- Wellcome Trust Translational Grants Reviewer & Expert Panel member.
- Grant Reviewer, British Skin Foundation, Psoriasis Association and Wellcome Trust.
- Fellow of the Royal College of Physicians, London and Edinburgh.
- Member of British Association of Dermatologists.
- Member of European Academy of Dermatology and Venereology.
- Member of British Society for Investigative Dermatology.
- Member of European Society for Dermatological Research.
- Member of British Society for Paediatric Dermatology.
- Member of Dowling Dermatology Society.
- Professional Member of the National Eczema Society.
- Member of The Council (board) of the Psoriasis Association.
- South Yorkshire Biotech Enterprise Network (SYBEN): York Pharma – Biotech company of the year, 2006.
- Yorkshire Forward Bioscience Yorkshire Annual Awards: Molecular Skin Care: Recognised for Outstanding Achievements in Bioscience. Awarded to the company who has made the greatest advances in Yorkshire in 2005.
- Leader of the team awarded ‘Health Care Professional Team of the Year’ by the National Eczema Society in 2004.
- Leader of the team awarded ‘Hospital Doctor Dermatology Team of the Year’ 2001.
- Enquiries
For Teaching & Academic Supervisory Enquiries, Post-Graduate and Undergraduate (i.e. PATs) please email:
Les Hunter & cc to Prof. Michael J. Cork
For Research Enquiries (including Pharmacological, Cosmetic & Academic) please email: Les Hunter & cc to Prof. Michael J. Cork
For Children’s Clinical NHS Enquiries please email: Elaine Cox & cc to Prof. Michael J. Cork
For Adult Clinical NHS Enquiries please email: Lucy Lowe & cc to Prof. Michael J. Cork